Agranulositosis

01Pathophysiology

Agranulocytosis refers to a severe reduction in circulating granulocytes, primarily neutrophils, defined by an absolute neutrophil count (ANC) below 500 cells/$\mu \backslash mu$L. The most profound form uses a threshold of < 100 cells/$\mu \backslash mu$L. On exams, the term is nearly synonymous with severe neutropenia and almost always appears in the context of a drug-induced etiology.

There are two principal mechanisms by which drugs cause agranulocytosis, and understanding each one explains the tempo and presentation of the clinical picture.

Direct myeloid toxicity (dose-dependent) occurs when the drug or its metabolite suppresses myeloid progenitor cells in the bone marrow. This follows a predictable, gradual course because it is proportional to drug exposure. The onset typically occurs weeks to months after starting the medication. Clozapine is the prototype for this mechanism. Because the damage accumulates over time, it can be detected early with regular blood monitoring before the patient becomes symptomatic. This is exactly why mandatory ANC monitoring is required for clozapine.

Immune-mediated destruction (idiosyncratic) is unpredictable and not dose-dependent. The drug acts as a hapten, binding to neutrophil surface proteins or myeloid precursors, triggering antibody- or complement-mediated destruction. Because this is an idiosyncratic reaction, it can occur at any dose and at any time, though it most often presents within the first few months of therapy. Methimazole and propylthiouracil (PTU) are classic examples. The onset tends to be sudden and dramatic, with patients presenting acutely ill.

The clinical consequences flow directly from the pathophysiology. Neutrophils are the first-line cellular defense against bacterial and fungal pathogens. When they are absent, the body cannot mount an adequate inflammatory response. This is why infected sites lack the classic signs of inflammation: there is no pus formation, no abscess wall, and minimal swelling, because all of those require neutrophil infiltration. The patient presents with mucosal ulceration (oropharynx, GI tract, perianal area) because mucosal surfaces are the primary interfaces with environmental pathogens. Fever is often the only sign of a life-threatening infection.

02Classification and Clinical Manifestation

Severity Classification by ANC

Mechanism-Based Classification

Clinical Manifestation by Site

High-Risk Drug List (Most Commonly Tested)

03Diagnostic Workup

The best initial test is a complete blood count (CBC) with differential. This is the first step whenever a patient on a known culprit drug presents with fever, sore throat, or mucosal ulceration. The hallmark finding is an ANC below 500 cells/$\mu \backslash mu$L. In drug-induced cases, other cell lines (red blood cells, platelets) may be normal or only mildly affected, which helps distinguish agranulocytosis from aplastic anemia and other causes of pancytopenia.

A peripheral blood smear should follow to evaluate cell morphology. In agranulocytosis, you will see a near-complete absence of mature neutrophils with preserved red cell and platelet morphology. The absence of blast cells on the smear is important because it helps rule out acute leukemia as the underlying cause of neutropenia.

If the patient is febrile (temperature $\ge \backslash geq$ 38.3°C or $\ge \backslash geq$ 101°F on a single reading, or $\ge \backslash geq$ 38.0°C / 100.4°F sustained over one hour), two sets of blood cultures must be drawn from separate sites before starting antibiotics. This is a non-negotiable step. The most common organisms isolated are gram-negative bacteria, particularly Pseudomonas aeruginosa, which carries high mortality in neutropenic patients. Gram-positive organisms (staphylococci, streptococci) are also common, especially with mucosal breakdown or indwelling catheters.

The most accurate test is a bone marrow biopsy. This is not always required in straightforward drug-induced cases where the clinical picture is clear, but it becomes necessary when the etiology is uncertain, the patient fails to recover after drug discontinuation, or there is concern for a primary hematologic disorder. The classic finding is maturation arrest at the promyelocyte or myelocyte stage, meaning early myeloid precursors are present but they fail to differentiate into mature neutrophils. In toxic-type agranulocytosis, you may see overall myeloid hypoplasia instead.

Additional workup depends on the clinical scenario. A chest X-ray is indicated if the patient has respiratory symptoms, but remember that the inflammatory infiltrate may be deceptively minimal because neutrophils are required to produce the typical consolidation pattern on imaging. Urinalysis may fail to show pyuria for the same reason: the absence of neutrophils means the absence of white cells in the urine even in the setting of a urinary tract infection.

04Management and Treatment

Step 1: Discontinue the offending drug.
This is the most important and most testable step. On the exam, when the vignette describes a patient on a known culprit drug presenting with fever and severe neutropenia, the "next best step" is always to stop the drug. Recovery of the ANC typically occurs within 1 to 3 weeks after drug cessation, depending on the mechanism. Immune-mediated cases may recover faster (within days) once the antigenic stimulus is removed, while toxic cases may take longer.

Step 2: Empiric broad-spectrum antibiotics for febrile neutropenia.
Any patient with an ANC < 500 and fever constitutes a medical emergency known as febrile neutropenia. Empiric antibiotics must be started within 60 minutes of presentation, ideally after blood cultures are drawn but never delayed for culture results. Monotherapy with an anti-pseudomonal beta-lactam is the standard:

• Cefepime 2g IV every 8 hours (most commonly tested first-line), OR

• Piperacillin-tazobactam 4.5g IV every 6 hours, OR

• Meropenem 1g IV every 8 hours (reserved for patients with beta-lactam allergy history that permits carbapenems, or high resistance risk)

Do not add vancomycin routinely. Vancomycin (15 to 20 mg/kg IV every 8 to 12 hours) should be added only when there is hemodynamic instability, suspected catheter-related infection, skin or soft tissue infection, known MRSA colonization, or severe mucositis.

Step 3: G-CSF (Granulocyte Colony-Stimulating Factor).
Filgrastim at a dose of 5 to 10 $\mu \backslash mu$g/kg/day subcutaneously is given as an adjunctive therapy to accelerate neutrophil recovery. It stimulates the proliferation and differentiation of granulocyte precursors in the bone marrow. Continue until the ANC recovers to > 1,000 cells/$\mu \backslash mu$L on two consecutive measurements. G-CSF has been shown to shorten the duration of neutropenia and reduce infection-related morbidity.

Step 4: Escalate if fever persists.
If the patient remains febrile after 4 to 7 days of appropriate broad-spectrum antibiotics, the concern shifts to invasive fungal infection (aspergillosis, candidiasis). Empiric antifungal therapy should be added:

• Caspofungin: 70mg IV loading dose on day 1, then 50mg IV daily, OR

• Liposomal amphotericin B: 3 to 5 mg/kg/day IV

Step 5: Supportive care and prevention.
Place the patient in a protected environment (single room, hand hygiene enforcement). Avoid rectal thermometers, rectal exams, and invasive procedures that could breach mucosal barriers. Document the culprit drug as a permanent allergy/adverse reaction in the patient's chart. If the drug is clozapine and re-initiation is being considered (which may be necessary for treatment-resistant schizophrenia), a strict monitoring protocol is required: weekly ANC for the first 6 months, biweekly for the next 6 months, then monthly thereafter.

Contraindications and special situations:

• In renal failure, dose-adjust vancomycin and meropenem. Cefepime requires careful dosing as neurotoxicity risk increases with renal impairment.

• In pregnancy, carbapenems and cephalosporins are generally safe. Avoid fluoroquinolones. G-CSF has limited safety data but has been used when the benefit outweighs risk.

• Do not use fluoroquinolone monotherapy for febrile neutropenia in high-risk patients (ANC < 100, expected duration > 7 days, hemodynamic instability). Oral fluoroquinolone plus amoxicillin-clavulanate is reserved only for low-risk outpatient febrile neutropenia (MASCC score $\ge \backslash geq$ 21).

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get this topic wrong is by failing to connect the drug history to the presentation. The vignette will describe a patient who recently started a new medication (or has been on one for a few weeks to months) and now presents with sudden fever and sore throat. Many students jump to a simple upper respiratory infection or pharyngitis and never order a CBC. The critical clue is the drug history combined with the severity of the mucosal findings (deep ulceration rather than simple erythema) and the absence of exudate or purulence. The lack of pus is counterintuitive but is the direct pathophysiologic consequence of having no neutrophils to form it.

A second common trap involves the sequencing of management. Students may be tempted to select "start G-CSF" as the next best step. While G-CSF is an important adjunct, the answer to "what is the next best step" in a febrile neutropenic patient is always (1) discontinue the drug, (2) draw blood cultures, and (3) start empiric broad-spectrum antibiotics within 60 minutes. G-CSF is supportive, not the primary intervention.

Another tested pearl: the vignette may describe a patient on clozapine who has a routine blood draw showing a declining ANC that has not yet crossed the threshold for agranulocytosis. The correct answer is to increase monitoring frequency or discontinue the drug before the patient becomes critically neutropenic. This tests your knowledge that clozapine mandates scheduled ANC surveillance precisely to prevent full-blown agranulocytosis.

Finally, watch for the "absent inflammatory signs" trap. A neutropenic patient with pneumonia may have a near-normal chest X-ray because infiltrate formation depends on neutrophilic inflammation. Similarly, a urinary tract infection may show no pyuria on urinalysis. If the vignette describes a febrile neutropenic patient with minimal findings on workup, do not be reassured. The absence of inflammatory markers reflects the severity of the immunodeficiency, not the absence of infection.

The core competency being tested is the ability to recognize drug-induced agranulocytosis as a medical emergency, identify the offending agent, and institute immediate, protocol-driven management: stop the drug, culture, cover with broad-spectrum antibiotics, and support recovery with G-CSF.